82 results
8-K
YMAB
Y-Mabs Therapeutics Inc
19 Feb 21
Y-mAbs Announces Proposed Public Offering of Common Stock
6:01am
to change upon completion of our financial statement closing procedures. There can be no assurance that such financial data for the year ended December … procedures with respect to the preliminary financial data. Accordingly, PricewaterhouseCoopers LLP does not express an opinion or any other form of assurance
424B5
YMAB
Y-Mabs Therapeutics Inc
17 Feb 21
Prospectus supplement for primary offering
6:02am
by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other … . However, we can provide no assurance that the FDA will agree with our proposal or that we will be successful in resubmitting our BLA for omburtamab
424B5
YMAB
Y-Mabs Therapeutics Inc
18 Feb 21
Prospectus supplement for primary offering
5:22pm
of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information … provide no assurance that the FDA will agree with our proposal or that we will be successful in resubmitting our BLA for omburtamab in this timeline